No one predicted rapid growth of gene therapy market, says CEO
After posting revenue growth of 39%, Repligen CEO suggests this was driven by filtration and chromatography franchises, particularly customers in gene therapy.
Archives for February 26, 2020
Takeda takes up $330m acquisition option for celiac treatment
Two years after first signing a partnership agreement and with Phase I results in, Takeda decides to snap up PvP Biologics.